These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 26586732)

  • 41. The potential role of anti-PCSK9 monoclonal antibodies in the management of hypercholesterolemia.
    Lepor NE; Contreras L; Desai C; Kereiakes DJ
    Rev Cardiovasc Med; 2014; 15(4):290-307; quiz 308-9. PubMed ID: 25662924
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials.
    Bays HE; Rosenson RS; Baccara-Dinet MT; Louie MJ; Thompson D; Hovingh GK
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):175-180. PubMed ID: 29627892
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
    Robinson JG; Farnier M; Krempf M; Bergeron J; Luc G; Averna M; Stroes ES; Langslet G; Raal FJ; El Shahawy M; Koren MJ; Lepor NE; Lorenzato C; Pordy R; Chaudhari U; Kastelein JJ;
    N Engl J Med; 2015 Apr; 372(16):1489-99. PubMed ID: 25773378
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism.
    Watts GF; Chan DC; Dent R; Somaratne R; Wasserman SM; Scott R; Burrows S; R Barrett PH
    Circulation; 2017 Jan; 135(4):338-351. PubMed ID: 27941065
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher.
    Ginsberg HN; Rader DJ; Raal FJ; Guyton JR; Baccara-Dinet MT; Lorenzato C; Pordy R; Stroes E
    Cardiovasc Drugs Ther; 2016 Oct; 30(5):473-483. PubMed ID: 27618825
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PCSK9 inhibition in patients with hypercholesterolemia.
    Desai NR; Sabatine MS
    Trends Cardiovasc Med; 2015 Oct; 25(7):567-74. PubMed ID: 25771732
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease.
    Toth PP; Dwyer JP; Cannon CP; Colhoun HM; Rader DJ; Upadhyay A; Louie MJ; Koren A; Letierce A; Mandel J; Banach M
    Kidney Int; 2018 Jun; 93(6):1397-1408. PubMed ID: 29526502
    [TBL] [Abstract][Full Text] [Related]  

  • 49. NMR-based lipoprotein analysis for patients with severe hypercholesterolemia undergoing lipoprotein apheresis or PCSK9-inhibitor therapy (NAPALI-Study).
    Schettler VJ; Muellendorff F; Schettler E; Platzer C; Norkauer S; Julius U; Neumann CL
    Ther Apher Dial; 2019 Oct; 23(5):467-473. PubMed ID: 30663261
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans.
    Reyes-Soffer G; Pavlyha M; Ngai C; Thomas T; Holleran S; Ramakrishnan R; Karmally W; Nandakumar R; Fontanez N; Obunike J; Marcovina SM; Lichtenstein AH; Matthan NR; Matta J; Maroccia M; Becue F; Poitiers F; Swanson B; Cowan L; Sasiela WJ; Surks HK; Ginsberg HN
    Circulation; 2017 Jan; 135(4):352-362. PubMed ID: 27986651
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of Evolocumab on Vitamin E and Steroid Hormone Levels: Results From the 52-Week, Phase 3, Double-Blind, Randomized, Placebo-Controlled DESCARTES Study.
    Blom DJ; Djedjos CS; Monsalvo ML; Bridges I; Wasserman SM; Scott R; Roth E
    Circ Res; 2015 Sep; 117(8):731-41. PubMed ID: 26228031
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.
    Blom DJ; Hala T; Bolognese M; Lillestol MJ; Toth PD; Burgess L; Ceska R; Roth E; Koren MJ; Ballantyne CM; Monsalvo ML; Tsirtsonis K; Kim JB; Scott R; Wasserman SM; Stein EA;
    N Engl J Med; 2014 May; 370(19):1809-19. PubMed ID: 24678979
    [TBL] [Abstract][Full Text] [Related]  

  • 53. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients With Acute Coronary Syndrome　- The ODYSSEY J-IVUS Trial.
    Ako J; Hibi K; Tsujita K; Hiro T; Morino Y; Kozuma K; Shinke T; Otake H; Uno K; Louie MJ; Takagi Y; Miyauchi K
    Circ J; 2019 Sep; 83(10):2025-2033. PubMed ID: 31434809
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia.
    Roth EM; McKenney JM; Hanotin C; Asset G; Stein EA
    N Engl J Med; 2012 Nov; 367(20):1891-900. PubMed ID: 23113833
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An evaluation of alirocumab for the treatment of hypercholesterolemia.
    Farnier M
    Expert Rev Cardiovasc Ther; 2015 Dec; 13(12):1307-23. PubMed ID: 26563849
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT).
    Koh KK; Nam CW; Chao TH; Liu ME; Wu CJ; Kim DS; Kim CJ; Li I; Li J; Baccara-Dinet MT; Hsiao PJ; Chiang CE
    J Clin Lipidol; 2018; 12(1):162-172.e6. PubMed ID: 29153823
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS Studies.
    Robinson JG; Colhoun HM; Bays HE; Jones PH; Du Y; Hanotin C; Donahue S
    Clin Cardiol; 2014 Oct; 37(10):597-604. PubMed ID: 25269777
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
    Joseph L; Robinson JG
    Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol.
    Colhoun HM; Leiter LA; Müller-Wieland D; Cariou B; Ray KK; Tinahones FJ; Domenger C; Letierce A; Israel M; Samuel R; Del Prato S
    Cardiovasc Diabetol; 2020 Feb; 19(1):14. PubMed ID: 32035487
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.